Navigation Links
Wayne State researcher developing treatments for Parkinson's with aid of $2.15 million NIH grant
Date:9/26/2011

DETROIT A Wayne State University professor is leading research efforts to develop new treatment options to slow the progression of Parkinson's disease, a neurodegenerative disorder that affects nearly six million people around the world, with 50,000 to 60,000 new cases diagnosed in the United States alone each year. Symptoms of Parkinson's disease may include tremor, slowed motion, rigid muscles, difficulty initiating movement, speech changes, postural instability and more.

Currently no ideal therapies are available for slowing the degeneration process while relieving symptomatic abnormalities associated with Parkinson's disease. Aloke Dutta, Ph.D., professor of pharmaceutical sciences in WSU's Eugene Applebaum College of Pharmacy and Health Sciences, is hoping to change that with a recently awarded $2.15 million research grant, Novel Neuroprotective Treatment for Parkinson's Disease, from the National Institute of Neurological Disorders and Stroke of the National Institutes of Health. Dutta and his team aim to develop multifunctional therapeutic agents that will be useful not only in symptomatic treatment of Parkinson's disease, but also as disease-modifying agents promoting survival of the dopamine neurons that would otherwise gradually degenerate in Parkinson's disease.

According to Dutta, the etiology of Parkinson's disease is poorly understood, but both oxidative stress and mitochondrial dysfunction resulting from loss of glutathione coupled with increased concentration of free iron have been strongly implicated in dopamine cell death. In this regard, alpha-synuclein, a protein involved in fibrillization, has also been connected to Parkinson's disease.

"It is increasingly evident that for a complex disease such as Parkinson's, a drug targeting only one specific site will only partially address the therapeutic needs of the disease," said Dutta. "A growing body of literature suggests that suitable multifunctional drugs might be more effective to act as disease modifying agents. The overall goal of our research is to develop multifunctional therapeutic agents which will be useful not only in symptomatic treatment, but also as disease-modifying agents promoting survival of dopamine neurons."

"Our initial studies indicate facile blood-brain barrier crossing ability of such compounds developed by us," said Dutta. "The lead drugs we are developing have shown positive results in animal models of Parkinson's disease, and one of our lead molecules is exhibiting a neuroprotection property that may be critical to slowing the further progression of Parkinson's disease while being symptomatically beneficial in alleviating motor dysfunction."

The team aims to begin pre-clinical validation of these treatment agents soon. If results are positive, Dutta's study would shift the current research paradigm of Parkinson's disease by expanding treatment beyond that of acute motor defects stemming from dopamine deficiency.


'/>"/>

Contact: Julie O'Connor
julie.oconnor@wayne.edu
313-577-8845
Wayne State University - Office of the Vice President for Research
Source:Eurekalert

Related medicine news :

1. Wayne State University study aims to improve diabetes management in high-risk youth
2. Wayne State University partners with Toyota on safety research
3. Wayne State University researcher to study spinal muscular atrophy
4. Wayne State University awarded $3 million from NIH to foster science and research careers
5. Wayne State researcher receives NSF award to develop neural implants
6. Wayne State University engineering student receives American Tinnitus Association award
7. Wayne State University researcher argues that sex reduces genetic variation
8. Health providers should emphasize breast cancer screening, Wayne State University research finds
9. Religion benefits traumatic brain injury victims, Wayne State University research finds
10. Wayne State University researchers win grant from the NSF to target tinnitus
11. Wayne State researchers find new way to examine major depressive disorder in children
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... ... , ... The American public tends to feel uncomfortable about drinking recycled waste ... or well water. The recent experience with lead contaminated water in Flint, Michigan, according ... toward increasing public acceptance of recycled waste water as drinking water. , The ...
(Date:2/5/2016)... SARASOTA, Fla., (PRWEB) , ... February 05, 2016 , ... ... appetizing recipes just in time for this weekend’s Big Game. Take the stress out ... ingredients that will keep your guests happy at every stage of the game. , ...
(Date:2/5/2016)... ... February 05, 2016 , ... Dr. Justin Scott and ... 2nd Annual No Cost Dental Day to individuals in need. The event is scheduled ... this No Cost Dental Day is to provide dental care to community members in ...
(Date:2/5/2016)... ... February 05, 2016 , ... Colorize is a web ... zone to the next using Colorize's dynamic moving camera. Colorize is perfect for personal ... a 3D slideshow environment with 1 to 5 focus points per scene, stage floor ...
(Date:2/5/2016)... ... , ... California Mobile Kitchens , a company that ... mobile kitchen model, featuring customizable stainless steel interiors and a new, 26-foot unit. ... anywhere in the U.S. Many of their units can be seen at sporting ...
Breaking Medicine News(10 mins):
(Date:2/4/2016)... Global Immunology Market to 2022 - ... market growth Summary Immune-mediated inflammatory diseases ... that affect 5–7% of western populations. Although they ... and key patient demographics, they are pathophysiologically linked, ... an inappropriate immune response. Generally, disease-modifying anti-rheumatic drugs, ...
(Date:2/4/2016)... Feb. 4, 2016 Mettler-Toledo International Inc. (NYSE: ... 2015.  Provided below are the highlights: , ... compared with the prior year.  Reported sales decreased 3% ... quarter. , Net earnings per diluted share as ... prior- year period.  Adjusted EPS was $4.65, an increase ...
(Date:2/4/2016)... 4, 2016  AMRI (NASDAQ:  AMRI) today announced that ... and President of Pfizer Global Supply, has been elected to ... 2016. In addition, the Company announced that Mr. Gabe ... since 2010, has retired from the AMRI Board of Directors ... other business ventures.  William S. Marth , ...
Breaking Medicine Technology: